Exelixis Inc

Financials

Flusso di cassa derivante dalle attività operative 333.51 M 884.27 M Flussi di cassa derivanti dalle attività di investimento 27.24 M 350.44 M Liquidità derivante dalle attività di finanziamento -254.57 M -969.59 M Liquidità libera 332.36 M 875.84 M

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

EXEL

Financials

Exelixis Inc

Notizie

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Exelixis alla Barclays Healthcare: crescita strategica e pipeline

Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights

Exelixis alla Leerink Global Healthcare Conference: approfondimenti strategici su RCC e CRC

Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC

Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Exelixis at TD Cowen: Strategic Vision and Growth

Le azioni Exelixis calano dopo risultati migliori dello studio di Merck

Exelixis stock falls after rival Merck trial shows better results